Skip to main content

COVID 19 Updates from RheumNow

CDC Reverses Stance on Masks

Today the Centers for Disease Control and Prevention (CDC) said that masks should be used by those vaccinated against the coronavirus in public indoor spaces in parts of the country where the virus is surging.

DMARD Effects on COVID-19 Outcomes

Sparks and colleagues have published data from the Global Rheumatology Alliance noting that among rheumatoid arthritis (RA) patients afflicted with COVID-19 infection, there was little influence of their baseline biologic or targeted synthetic (b/ts) disease-modifying antirheumatic drugs (DMARDs)

Canakinumab Fails to Improve COVID-19 Survival

JAMA has published the findings of trial wherein the anti–interleukin-1β antibody canakinumab (CAN) failed to improve survival in patients hospitalized with severe COVID-19.

Rare Myocarditis Risk following COVID-19 Vaccine

CDC/MMWR

MMWR review of the risk of myocarditis and pericarditis reports a June 23, 2021 recommendation by the Advisory Committee on Immunization Practices that the benefits of COVID-19 vaccination clearly outweighed the risks of myocarditis after vaccination. 

ICYMI: RheumNow Podcast – Tofacitinib Safety Concerns

Dr. Jack Cush reviews and discusses the news and journal reports from the past week on RheumNow.com.

ICYMI: 2020 Rheumatology Year in Review

2020 was historic, memorable and game-changing. Under the cloud of COVID-19, there were many significant and memorable advances and setbacks for the rheumatology world. In our accounting of most read articles for 2020, (not surprisingly) 17/20 were COVID-related.

RheumNow Podcast – As Good As I Ever Was (7.2.2021)

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com.

RheumNow Podcast – Modern Treatment of RA Pregnancy (6.25.2021)

Dr. Jack Cush reviews this week’s news and journal reports featured on RheumNow.com.

Birthday Gatherings Increase COVID-19 Risk

How risky are family gatherings, birthday parties and informal social gatherings? A cross-sectional analysis suggests that birthdays may be associated with increased rates of COVID-19 infection within households where there is a high COVID-19 prevalence in the population. 

Treatment of MIS-C COVID in Kids

The NEJM has published results of a real-world efficacty trial showing that COVID infected children with the multisystem inflammatory syndrome in children (MIS-C) respond better to initial IVIG plus glucocorticoids (than IVIG alone) which was associated with less subsequent cardiovascular complic

Tofacitinib Efficacy in COVID-19 Pneumonia

NEJM has published the results of an observational trial wherein tofacitinib given to patients hospitalized with Covid-19 pneumonia, was shown to significantly lower risk of death or respiratory failure.

EULAR 2021 – Day 4 Report

Lots of presentations on the last day; notably, the late breaking abstracts and others. Here are a few of my favorites from Day 4.

Social

Health personnel (HCP) @ long-term care facilities (LTCFs) are at high risk for COVID-19. March 2021, 57% of LTCF HCPs were vaccinated. COVID-19 vax was highest in MDs (75.1%); lowest nurses (56.7%) & aides (45.6%). https://t.co/VjHutcrh26

Dr. John Cush @RheumNow ( View Tweet )

4 hours 58 minutes ago
The FDA has authorized baricitinib ALONE as treatment for COVID-19 hospitalized adults and pediatric patients requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) https://t.co/WMc78GmOLU

Dr. John Cush @RheumNow ( View Tweet )

5 hours 11 minutes ago
Persistence of Sxs & Labs long after COVID. German study of 96 postCOVID pts followed 12 mos only 22% were Sx-free; Most had fatigue (53%), dyspnea (37%), concentration (40%), CNS (32%) & sleeping problems (26%), +ANA ≥1:160 in 44% https://t.co/L2ZzniDT18

Dr. John Cush @RheumNow ( View Tweet )

1 day 9 hours ago
#VaccinationCovid DOES induce #SARS_CoV_2-specific #antibodies in #Rituximab-treated patients, after peripheral B-cells have at least partially repopulated! In addition, T cell responses (independent of B cell status) may also exert protective effects! https://t.co/E1FErHJtd3

Daniel Aletaha @DanielAletaha ( View Tweet )

1 week 1 day ago
Canakinumab Fails to Improve COVID-19 Survival https://t.co/ngThAgfHTq JAMA has published the findings of trial wherein the anti–interleukin-1β antibody canakinumab (CAN) failed to improve survival patients hospitalized with severe COVID-19. https://t.co/pUBmt85jAC
Dr. John Cush @RheumNow ( View Tweet )
1 week 1 day ago
152 Israeli pts w/ Breakthrough COVID infx >7d after 2nd Pfizer vax; all hospitalized, 38 w/ Poor outcome & 22% (34/152) died. All were older, most males, w/ comorbidities, 40% immunocompromised; high risk w/ RTX & low anti-spike IgG titers https://t.co/x1Uuyo7qim

Dr. John Cush @RheumNow ( View Tweet )

1 week 2 days ago
Vaccinated COVID-19 pts appear less contagious; report from Israel - among 650,000 received two-doses of Pfizer vaccine, 2,897 later tested positive for COVID-19, but nasal swab samples showed 4-fold less virus - hinting protection https://t.co/UBE4q5T2Ht https://t.co/OOgWoqdkdt
Dr. John Cush @RheumNow ( View Tweet )
2 weeks 6 days ago
Protective Effects of Colchicine in Non-Hospitalized COVID-19 A press release from the Montreal Heart Institute has announced that the COLCORONA clinical trial has provided evidence of the protective effect of colchicine. Read more: https://t.co/xW5SchMUeK https://t.co/tUoDTJKbVG
Dr. John Cush @RheumNow ( View Tweet )
3 weeks 3 days ago
How risky are family gatherings, birthday parties and informal social gatherings? Read more… https://t.co/jyGHakndUt https://t.co/7eps0EFVWy
Dr. John Cush @RheumNow ( View Tweet )
3 weeks 5 days ago
CDC: as of 5/15/2021; the rates of flu test positivity was 0.051-0.18% for the 2020-21 flu season - compared to usual rate of 10%-19% before COVID. Actual influenza hospitalizations dropped from 44.2 to 0.8/100 000 population https://t.co/N8b1sQWWIh

Dr. John Cush @RheumNow ( View Tweet )

4 weeks ago
×